Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Exalenz Bioscience Stories

2013-07-23 08:30:07

JERSEY CITY, N.J., July 23, 2013 /PRNewswire/ -- Exalenz Bioscience (TASE: EXEN), developer of advanced diagnostic systems that use a patient's breath to detect and help manage gastrointestinal and liver conditions, today named Gavin Doree the company's new vice president of sales. Today's news follows the world market launch of the BreathID(®) Hp, a second generation device, that using the real-time, continuous breath of a patient, detects the presence of the H. pylori bacteria,...

2013-07-15 08:26:45

Exalenz adopts new sales approach and other changes to provide superior customer service, training and support. JERSEY CITY, N.J., July 15, 2013 /PRNewswire/ -- Exalenz Bioscience (TASE: EXEN), developer of advanced diagnostic systems that use a patient's breath to detect and help manage gastrointestinal and liver conditions, announced today the global launch of the BreathID Hp, a next generation device in the company's BreathID product line. BreathID Hp facilitates a 'test and...

2012-07-09 23:02:26

Exalenz to Supply Innovative H. pylori Breath Testing Solution to Veterans Administration Hospitals and Clinics Wilmington, Del. (PRWEB) July 09, 2012 Exalenz Bioscience, a worldwide provider of breath testing equipment for the diagnosis and management of digestive system and liver conditions, today announced it has been awarded a GSA contract. With this contract, Exalenz´ novel point-of-care breath test for Helicobacter pylori (H. pylori), the BreathID® System, is now on the...